12DNA today announced record-breaking results for the third quarter of 2023. The company achieved significant growth in revenue and profitability, driven by strong demand for its gene editing services and partnerships with leading pharmaceutical companies. This success reflects 12DNA’s position as a leader in the rapidly growing gene editing market.
Menu